COMPOUNDS AND METHODS FOR REDUCING IFNAR1 EXPRESSION

Abstract: provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ifnar1 rna in a cell or an animal, and in certain instances, reducing the amount of ifnar1 protein in a cell or animal. such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to treat diseases and conditions associated with neuroinflammation, including aicardi-goutieres syndrome, stroke, neuropsychiatric systemic lupus erythematosus, neuroinflammation following traumatic brain injury, neuro-autoimmune disorders, alzheimer's disease, post-operative delirium and cognitive decline, cranial radiation-induced cognitive decline, viral infection-induced cognitive decline, neuromyelitis optica, and ataxia telangiectasia.

Inventor(s): Fredrik Carl Kamme, Huynh-Hoa Bui, Susan M. Freier, Swagatam Mukhopadhyay

CPC Classification: C12N15/1138 ({against receptors or cell surface proteins})

Search for rejections for patent application number 20250188476